Loading…
Orphan Drug COVID–19 Mitigation Act of 2022
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Orphan Drug COVID-19 Mitigation Act of 2022 This bill extends by 180 days the relevant periods of market exclusivity for drugs for rare diseases or conditions (i.e., orphan drugs) for which applications were submitted during the COVID-19 emergency period.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (6)
2023 · first_quarter · Pharmacy
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
H.R.5376 - Inflation Reduction Act of 2022 (117th) H.R.2471 - Consolidated Appropriations Act, 2022 (117th) H.R.485 - Protecting Health Care for All Patients Act of 2023 H.R.1350 - Camerons Law H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022 (117th) S.46 - American Innovation and Manufacturing Act
Client expense: Not reported · Firm income: $60,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Client expense: $250,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Issues related to the development of therapies for rare diseases and sleep disorders. Drug pricing. Access to non-controlled medications. PDUFA Reauthorization. H.R.6000 - Cures 2.0 Act. FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169). H.R.5585 - Advanced Research Project Agency-Health (ARPA-H) Act. H.R.6963 - Accelerated Approval Integrity Act of 2022. H.R.2623 - Camerons Law. H.R.7667 - Food and Drug Amendments of 2022. S.4348 - FDASLA Act of 2022. H.R.6833 - Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180). H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022. H.R.1730/S.670 - Speeding Therapy Access Today (STAT) Act of 2021. Issues related to raising awareness of World Narcolepsy Day.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Taxation/Internal Revenue Code
Issues related to the development of therapies for rare diseases and sleep disorders. Drug pricing. Access to non-controlled medications. PDUFA Reauthorization. H.R.6000 - Cures 2.0 Act. FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169). H.R.5585 - Advanced Research Project Agency-Health (ARPA-H) Act. H.R.6963 - Accelerated Approval Integrity Act of 2022. H.R.2623 - Camerons Law. H.R.7667 - Food and Drug Amendments of 2022. S.4348 - FDASLA Act of 2022. H.R.6833 - Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180). H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022. H.R.1730/S.670 - Speeding Therapy Access Today (STAT) Act of 2021.
Client expense: Not reported · Firm income: $50,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R.2617 - Consolidated Appropriations Act, 2023; Provisions Related to Healthcare H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill Issues related to rare disease Issues related to patient access treatments
Client expense: $180,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · fourth_quarter · Health Issues
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Client expense: $250,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R.1730/S.670, The Speeding Therapy Access Today (STAT) Act of 2021; H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021;
Client expense: Not reported · Firm income: $20,000
2022 · third_quarter · Health Issues
Issues related to the development of therapies for rare diseases and sleep disorders. Drug pricing. Access to non-controlled medications. PDUFA Reauthorization. H.R.6000 - Cures 2.0 Act. FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169). H.R.5585 - Advanced Research Project Agency-Health (ARPA-H) Act. H.R.6963 - Accelerated Approval Integrity Act of 2022. H.R.2623 - Camerons Law. H.R.7667 - Food and Drug Amendments of 2022. S.4348 - FDASLA Act of 2022. H.R.6833 - Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180). H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022. H.R.1730/S.670 - Speeding Therapy Access Today (STAT) Act of 2021. Issues relatred to raising awareness of World Narcolepsy Day.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Taxation/Internal Revenue Code
Issues related to the development of therapies for rare diseases and sleep disorders. Drug pricing. Access to non-controlled medications. PDUFA Reauthorization. H.R.6000 - Cures 2.0 Act. FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169). H.R.5585 - Advanced Research Project Agency-Health (ARPA-H) Act. H.R.6963 - Accelerated Approval Integrity Act of 2022. H.R.2623 - Camerons Law. H.R.7667 - Food and Drug Amendments of 2022. S.4348 - FDASLA Act of 2022. H.R.6833 - Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180). H.R.8641 - Orphan Drug COVID-19 Mitigation Act of 2022. H.R.1730/S.670 - Speeding Therapy Access Today (STAT) Act of 2021.
Client expense: Not reported · Firm income: $50,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021;
Client expense: Not reported · Firm income: $20,000
2022 · third_quarter · Health Issues
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R.1730/S.670, The Speeding Therapy Access Today (STAT) Act of 2021.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; access to non-controlled medications; PDUFA Reauthorization; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.6963, Accelerated Approval Integrity Act of 2022; H.R.2623, Camerons Law; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.8641, Orphan Drug COVID-19 Mitigation Act of 2022; H.R. 1730/S. 670, The Speeding Therapy Access Today (STAT) Act of 2021.
Client expense: $250,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE